Drug Updates

The Challenges of Oral Cancer Drugs Use and Side-Effects Management

“There’s a human behind the patient, and he can tell us what he needs. He’s really the expert in the field,” Christine B. Boers-Doets, MSc, Netherlands Leiden University Medical Center, told attendees at the recent ESMO International Consensus Conference for Advanced Breast Cancer.

Read More ›

Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation

For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase inhibitor in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results presented at the 2017 ESMO Congress.

Read More ›

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate of 41.6% in a phase 1 dose-escalation and expansion clinical trial of patients with relapsed or refractory acute myeloid leukemia and IDH1 mutation, according to data presented at ASH 2017.

Read More ›

In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia. Read More ›

Oncology nurses may believe that personal exposure to hazardous drugs is a thing of the past, but they would be wrong. Read More ›

This therapy is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD) who develop renal or pulmonary dysfunction after undergoing hematopoietic SCT. Read More ›

Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner. Read More ›

Recent surveys of oncologists and hematologists show that drug shortages persist, that practitioners are adapting in ways that often raise the cost of cancer care, and that most have no guidance to aid in decision making in the face of these shortages. Read More ›

This is the third article in a 4-part series on bendamustine. While the previous article discussed the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling, this article discusses its safety Read More ›

Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL). Read More ›

Page 2 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: